
Getting started
Your prescriber sets a starting dose and plan for you. The early days focus on settling in.
10% OFF
Overview
Account
Overview
Treatments
Account
Be the first to know when Foundayo - Orforglipron is available. Choose your preferred dose and we'll email you.
Get an email as soon as Foundayo is available.
NoteBMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber once treatment is available.
Once-daily oral GLP-1 treatment for eligible adults. The active ingredient in Foundayo is orforglipron, a GLP-1 receptor agonist that has been approved for use in the UK for weight management alongside a calorie-reduced diet and increased physical activity.
Foundayo is a prescription medicine, and a prescriber must evaluate your suitability for the product before it can be dispensed.
Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly.
In the UK, Foundayo is authorised for weight management in adults with:
It is used alongside a reduced-calorie diet and increased physical activity.
In addition to weight management, Foundayo is also approved for adults with type 2 diabetes that is inadequately controlled, to improve blood glucose control, either as a monotherapy or in combination with other diabetes medications. Because Foundayo is a prescription medication, eligibility is based on a determination made by a healthcare provider rather than solely on BMI.
Foundayo contains orforglipron, which functions by activating the GLP-1 receptor. GLP-1 is a hormone associated with the regulation of appetite, food intake and blood glucose control. By activating the GLP-1 receptor, orforglipron can influence appetite and assist in decreasing food intake while simultaneously affecting blood glucose control.
Additionally, Foundayo causes delayed gastric emptying, particularly during initial treatment. However, this effect diminishes as treatment progresses.
The result of using Foundayo is not merely observing a decrease in numbers on the scale. Foundayo is intended to be used as part of a comprehensive weight management programme that incorporates diet modifications and physical activity.
When using Foundayo for weight management purposes, the objective is not solely to achieve short-term weight loss. Both weight loss and weight maintenance in eligible adults are covered under the UK indication.
Studies revealed statistically significant weight reductions when comparing orforglipron to placebo when combined with diet and physical activity. Individual weight loss results differed based on dose and participant characteristics.
During Phase III ATTAIN trials, participants received escalating doses of orforglipron and were provided with support related to healthy eating habits and increased physical activity throughout the trial duration. This is relevant since Foundayo is not intended to replace positive lifestyle changes; rather, it is intended to supplement them.
Foundayo is designed to commence at a minimal dose and gradually escalate.
The current UK dosing schedule begins with:
| Strength | Typical stage |
|---|---|
| 0.8 mg | Starting dose |
| 2.5 mg | After at least 30 days |
| 5.5 mg | After at least 30 days on the current dose |
| 9 mg | Further increase if appropriate |
| 14.5 mg | Further increase if appropriate |
| 17.2 mg | Maximum daily dose |
Dose escalations depend upon treatment response and tolerability. Your prescriber will determine whether and when your dose should be increased. Do not increase your dose without consulting your prescriber. The maximum daily dose is 17.2 mg once daily. Do not take additional tablets in an effort to achieve a greater dose.
Foundayo is taken once a day.
You can take it:
Swallow the tablet whole. Do not break, crush or chew the tablet.
If you miss a dose, follow the instructions provided with your medicine or speak to your pharmacist or prescriber. Do not take more than one tablet in a day to make up for a missed dose.
Foundayo is not formulated to produce an immediate weight-loss effect. Weight changes occur as treatment progresses and doses are gradually increased in accordance with your response and tolerability. Clinical studies evaluated weight change over several months rather than after a single dose.
This is essential when establishing expectations. Failure to experience significant weight loss during the initial days does not imply that the medicine is ineffective. Your prescriber can assess your progress and establish whether continuation or modification of treatment is warranted.
Like all medications, Foundayo may result in adverse reactions, although not all individuals experience them. The most common adverse reactions reported are gastrointestinal, particularly during dose escalation.
These can include:
These effects are generally more common while the dose is being increased and may become less troublesome over time.
If gastrointestinal symptoms are severe or persistent, speak with your prescriber rather than simply trying to push through them.
Foundayo has important safety warnings that should be understood before treatment.
Acute pancreatitis has occurred with orforglipron. Seek immediate medical attention if you develop prolonged, intense abdominal pain, especially if the pain radiates towards your back. If pancreatitis is suspected, treatment should be discontinued and evaluated by a healthcare provider.
Foundayo can induce gastrointestinal adverse reactions and delay gastric emptying. It has not been studied in people with severe gastrointestinal disease, including severe gastroparesis, and caution is required in these situations.
Vomiting and diarrhoea can cause loss of fluids. Significant dehydration can affect kidney function. Make sure your prescriber knows if you have experienced significant vomiting, diarrhoea or dehydration.
Hypoglycaemia risk is heightened when Foundayo is administered alongside insulin or sulfonylureas. Your prescriber may need to evaluate your treatment regimen and blood glucose monitoring if you use diabetes medications.
Foundayo is not appropriate for all individuals.
Your prescriber needs to know about your:
Foundayo is contraindicated in individuals with known hypersensitivity reactions to orforglipron or any constituent thereof. It is also not recommended for people with severe hepatic impairment. The safety and effectiveness of Foundayo in people under 18 have not been established.
Foundayo should not be used during pregnancy.
Consult with your healthcare professional before using Foundayo if you are pregnant, thinking about becoming pregnant, or planning for pregnancy.
Do not use Foundayo while breastfeeding, since it is unknown whether orforglipron is excreted into human breast milk and there remains uncertainty regarding potential harm to newborns and infants.
Inform your prescriber about all medications that you use, including those purchased over the counter. Do not start using another prescription weight-loss medication alongside Foundayo unless specifically directed by your prescriber.
This is particularly important if you take medicines for:
Foundayo can delay gastric emptying, which may affect the absorption rates of orally administered medications. There are also specific interactions involving medicines that affect the CYP3A4 and OATP1B pathways.
If you take insulin or a sulphonylurea, your risk of low blood sugar may increase and your diabetes treatment may need adjustment.
One of the most obvious differences is the way Foundayo is taken.
| Feature | Foundayo | Injectable GLP-1 medicines |
|---|---|---|
| Active ingredient | Orforglipron | Depends on medicine |
| Form | Tablet | Injection |
| Frequency | Once daily | Depends on medicine |
| Food restrictions | None | Depends on medicine |
| Prescription | Yes | Yes |
| Used with lifestyle changes | Yes | Yes |
Foundayo is an oral GLP-1 receptor agonist and therefore provides an alternative form of administration for eligible adults who receive prescriptions for it.
However, different GLP-1 receptor agonists have distinct indications, dosages, schedules, efficacy data and safety profiles, so they should not be viewed as interchangeable products.
Foundayo represents a distinct class of medications relative to traditional appetite suppressants and other oral weight-management medications. Its active ingredient, orforglipron, is a GLP-1 receptor agonist.
A more appropriate comparison is based on which medication is most suitable for you rather than which tablet is "strongest". Your prescriber will evaluate various factors when making a recommendation, including:
The optimal choice depends upon individual circumstances rather than a universal answer.
Each Foundayo tablet contains orforglipron as the active ingredient.
The tablet also contains excipients including:
The film coating contains ingredients including poly(vinyl alcohol), titanium dioxide, macrogol and talc, with different iron oxide colours used in some strengths.
If you have a known allergy or intolerance, check the patient information leaflet supplied with your medicine and tell your prescriber or pharmacist before taking Foundayo.
Foundayo was authorised in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) in August 2026.
It is a prescription-only medicine. That means you cannot simply add Foundayo to a basket and have it supplied without the appropriate clinical process.
If you are considering Foundayo through an online pharmacy, check that the service clearly explains:
The price of Foundayo may vary according to the strength, pack size, dispensing service and any current offers.
Because prescription medicine prices can change, check the current product selection for the latest strength, pack size and price before ordering.
When searching for "Foundayo online", "Foundayo weight loss tablets" or "orforglipron UK", bear in mind that Foundayo is a prescription medication. A suitable treatment and dose must be determined via clinical assessment. EverydayMeds provides a consultation process wherein a prescriber reviews your medical history, current medications and eligibility before issuing a prescription where clinically warranted. Never purchase orforglipron from an unverified source merely because it appears less costly.

Your prescriber sets a starting dose and plan for you. The early days focus on settling in.

Cravings ease off, and eating well starts to feel less like a fight.

You'll feel it before the scales show it — more energy, a bit more like yourself.

Some weeks are harder than others. Your care team keeps you on track.

Now it's about holding on to what you've built. No rush, no pressure.

Your whole journey in one app — how, simply, all in one pocket.
Achieve your goals in just a few simple steps.

Select safe UK treatments. Quick answers.

Our expert team will use your consultation as the basis of our recommendation and communicate with you.

We'll deliver direct to you, as quickly as tomorrow.
Everything you need to know about this clinic.